Granulocytic sarcoma of the breast in acute myeloid leukemia: Two case reports

Oncology Letters
Jianfei Fu, Jiansheng Luo

Abstract

Granulocytic sarcoma (GS) of the breast is extremely rare in patients with acute myeloid leukemia (AML) and therefore, is often misdiagnosed as lymphoma or other benign tumors. The current report presents two cases of GS of the breast, of which, one was considered to be a fibroma, as observed by fine-needle aspiration, and the other was misdiagnosed as lymphoma by frozen section. Previous literature that described the clinical and pathological characteristics, treatments and prognosis of GS of the breast in AML were reviewed. In addition to the treatment of mastectomy with/without radiotherapy, lumpectomy may also be received as a good treatment plan.

References

Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdN A Dawson
Oct 1, 1993·The American Journal of Surgical Pathology·S T TraweekR K Brynes
Jul 6, 2000·European Radiology·N J KhouryA I Shamseddine
Nov 9, 2000·Seminars in Ultrasound, CT, and MR·W T YangL W Ho
Oct 26, 2007·Annals of the Royal College of Surgeons of England·Jecko ThachilGraham Copeland
Jul 12, 2008·Hematology·Merat Karbasian-EsfahaniLool Abebe

❮ Previous
Next ❯

Citations

Sep 29, 2015·Archives of Pathology & Laboratory Medicine·Martin K IshikawaJulie M Jorns
Aug 8, 2015·Clinical Nuclear Medicine·Li-Chun ZhengXiao-Ming Zhang
Dec 2, 2015·Oncology Letters·Xiao-E HuangXiao-Dong Zhou
Oct 9, 2016·Pediatric Radiology·Michele N EdisonJennifer L Williams

❮ Previous
Next ❯

Methods Mentioned

BETA
bone
biopsy
bone marrow aspiration

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.